Boston Scientific Corporation $BSX Holdings Trimmed by iA Global Asset Management Inc.

iA Global Asset Management Inc. reduced its position in shares of Boston Scientific Corporation (NYSE:BSX) by 16.7% during the 1st quarter, Holdings Channel.com reports. The firm owned 171,827 shares of the medical equipment provider’s stock after selling 34,356 shares during the period. iA Global Asset Management Inc.’s holdings in Boston Scientific were worth $10,782,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of BSX. Renaissance Group LLC acquired a new position in Boston Scientific in the 4th quarter worth about $28,064,000. Rathbones Group PLC lifted its holdings in shares of Boston Scientific by 20.9% during the 4th quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock valued at $263,133,000 after buying an additional 477,680 shares during the last quarter. Tounjian Advisory Partners LLC bought a new stake in shares of Boston Scientific in the 4th quarter valued at approximately $1,477,000. Waycross Partners LLC acquired a new position in Boston Scientific in the fourth quarter worth approximately $2,384,000. Finally, Kepler Cheuvreux Suisse SA acquired a new position in Boston Scientific in the third quarter worth approximately $26,955,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific completed its POLARx Post Approval Study, adding fresh clinical data to its atrial fibrillation growth story and supporting the long-term outlook for its electrophysiology business. Boston Scientific’s POLARx Study Completion Adds Fresh Data to Atrial Fibrillation Growth Story
• Positive Sentiment: The company’s latest reported revenue growth remains strong, with Q1 sales up 11.6% year over year, which helps reinforce the durability of Boston Scientific’s core medtech franchise.
• Neutral Sentiment: Boston Scientific invested $1.5 billion for a 34% stake in MiRus and secured an option to buy its TAVR system, a strategic move that could expand its structural heart pipeline over time. Boston Scientific (BSX) Invests $1.5B in MiRus for Equity Stake and TAVR Acquisition Option
• Neutral Sentiment: Stifel lowered its price target to $65 from $75 but kept a Buy rating, while other analysts also trimmed earnings estimates only slightly; the cuts suggest some caution, but not a full deterioration in the long-term thesis. Stifel Cuts PT on Boston Scientific Corporation (BSX)- Here’s Why
• Negative Sentiment: Recent analyst commentary and social-media chatter focused on softer demand for the Watchman device, bundling pressure, and technical weakness near multi-year lows, which likely contributed to the stock’s decline. Boston Scientific Stock (BSX) Opinions on Recent Analyst Downgrades
• Negative Sentiment: Boston Scientific also declined in the latest session despite a broader market gain, reflecting investor concern that recent analyst revisions and product-specific pressures may outweigh the company’s fundamental growth. Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $42.98 on Thursday. The company has a market cap of $63.88 billion, a price-to-earnings ratio of 17.98, a PEG ratio of 0.82 and a beta of 0.58. The business has a 50 day moving average price of $51.68 and a 200 day moving average price of $69.93. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a twelve month low of $42.25 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same period in the previous year, the business posted $0.75 EPS. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Research analysts predict that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific declared that its board has approved a stock repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Insider Transactions at Boston Scientific

In related news, Director Edward J. Ludwig acquired 3,580 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were bought at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the acquisition, the director owned 25,359 shares in the company, valued at $1,437,348.12. This trade represents a 16.44% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Cheryl Pegus acquired 1,770 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were bought at an average cost of $56.49 per share, with a total value of $99,987.30. Following the transaction, the director directly owned 1,770 shares of the company’s stock, valued at $99,987.30. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have purchased 9,800 shares of company stock worth $554,012. Insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. The Goldman Sachs Group set a $71.00 target price on shares of Boston Scientific in a research note on Thursday, May 28th. Wells Fargo & Company restated an “equal weight” rating and set a $55.00 price target (down from $75.00) on shares of Boston Scientific in a report on Thursday, May 28th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Boston Scientific in a research note on Thursday, May 28th. Mizuho lowered their target price on shares of Boston Scientific from $115.00 to $90.00 and set an “outperform” rating on the stock in a research report on Monday, April 13th. Finally, Weiss Ratings downgraded shares of Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $83.36.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.